AstraZeneca has admitted that its COVID-19 vaccine could cause a rare but deadly blood-clotting condition, potentially exposing the UK pharmaceutical giant to tens of millions in lawsuits brought ...

AstraZeneca AZN3.10%increase; green up pointing triangle has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

The pharmaceutical giant AstraZeneca on Tuesday said it is withdrawing its COVID-19 vaccine worldwide citing low demand and a "surplus of available updated vaccines" since the pandemic.

AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight ...

AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand. The vaccine — called Vaxzevria and ...

Making wealth creation easy, accessible and transparent. AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they’re continuing to increase investment ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

Nov 1 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday it would invest $245 million in French biotechnology company Cellectis (ALCLS.PA), opens new tab in a deal aimed at speeding ...

AstraZeneca AZN1.05%increase; green up pointing triangle plans to invest $2.5 billion in China over five years to build a research-and-development center and strike deals with local biotechnology ...